Search
Bioqian Biotech, a clinical-stage drug R&D enterprise driven by innovation, has recently announced the successful completion of over 200 million yuan in Series A funding. This latest round of financing was spearheaded by Longpan Investment, with participation from Shanghai Science and Innovation Fund, Pudong Venture Capital, Shangshi Capital, and Capital Today. The proceeds from this funding will be pivotal in expediting the registration and clinical trial process for Bioqian's groundbreaking CD3L1-targeted antitumor drug, a global first-in-class therapy. Additionally, the funds will propel the company's R&D efforts in developing multiple new target tumor treatment pipelines. Founded by Dr. Xu Jie, Bioqian Biotech is a pioneer in the realm of tumor immunotherapy.
-
C114 Communication Network -
Communication Home
